ATOSSA THERAPEUTICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $21.2M | $14.1M | $17.3M | $15.1M | $9.2M | $6.6M | $6.6M |
| SG&A Expense | — | $16.0M | $13.5M | $14.0M | $12.6M | $11.3M | $8.0M | $10.6M |
| Operating Income | — | $-37.1M | $-27.6M | $-31.4M | $-27.7M | $-20.5M | $-14.6M | $-17.3M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-34.8M | $-25.5M | $-30.1M | $-27.0M | $-20.6M | $-17.8M | $-17.2M |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $-34.8M | $-25.5M | $-30.1M | $-27.0M | $-20.6M | $-17.8M | $-17.2M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-4.04 | $-3.04 | $-0.24 | $-0.21 | $-0.18 | $-1.97 | $-2.03 |
| EPS (Diluted) | — | $-4.04 | $-3.04 | $-0.24 | $-0.21 | $-0.18 | $-1.97 | $-2.03 |
| Shares Outstanding (Basic) | 8.6M | 8.6M | 8.4M | 126.1M | 126.6M | 117.0M | 47.6M | 9.1M |
| Shares Outstanding (Diluted) | 8.6M | 8.6M | 8.4M | 126.1M | 126.6M | 117.0M | 47.6M | 9.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |